New York Ban On Psychiatric drug tests

2 April 1995

A New York judge has ordered the state Department of Health to stop experiments on children and mentally-ill patients who are not competent to give their consent until the Department writes new rules for such experiments. An appeal is now underway.

At present, hundreds and possibly thousands of patients in psychiatric institutions are receiving experimental drug treatments for illnesses including extreme psychosis, Alzheimer's disease and schizophrenia, based on consent from relatives and friends. The halted experiments apply to adult patients who are not competent to give their consent, experiments on children that are nontherapeutic and intended only to obtain information for another purpose, and experiments on children to which parents have not consented.

The nonprofit organization Disability Advocates, which brought the lawsuit, claims that the 1990 regulations which were intended to be more sensitive to patients' rights do not go far enough to protect the patients. The central issue, according to the New York Times, is that the regulations allow the Office of Mental health to put mentally-ill patients and children in experiments with the consent of surrogates, and it claims that each type of experiment harbors the possibility of serious abuse.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight